1
|
Solidified Reverse Micellar Solution- (SRMS-) Based Microparticles for Enhanced Oral Bioavailability and Systemic Antifungal Efficacy of Miconazole Nitrate in Immunocompromised Mice. BIOMED RESEARCH INTERNATIONAL 2022; 2022:8930709. [PMID: 35118159 PMCID: PMC8807030 DOI: 10.1155/2022/8930709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 10/13/2021] [Accepted: 01/16/2022] [Indexed: 11/18/2022]
Abstract
Purpose. To assess the improvement in oral bioavailability and efficacy in systemic candidiasis treatment of miconazole nitrate (MN) formulations in murine models of candidiasis. Methods. Selected formulations containing 5% of
90H lipid matrix with 3% of MN (
), 5% of
90H lipid matrix with 3% of MN (
), and 5%
90H with 3% of MN (
) from the in vitro investigation were used for the study. Their acute toxicity was assessed using Lorke’s method (with slight modification) while bioavailability was determined using the bioassay method. The optimized batch (
) was tested in murine systemic candidiasis induced in cyclophosphamide-immunosuppressed mice. The mice were treated with a single oral dose (100 mg/kg) of the formulations for five days. Serum fungal counts (cfu/mL) were determined on days 1, 3, and 5 of the treatment period. Haematological assessments were done. Results. The lipid formulations were safer than MN powder with LD50 values of 3162.8 and 1118.3 mg/kg. Bioavailability determination revealed a higher area under the curve (AUC) value for formulations
(6.11 μg/hr/mL) and
(4.91 μg/hr/mL) while formulation
(1.80 μg/hr/mL) had a lower AUC than MN (4.46 μg/hr/mL). Fungi were completely cleared from the blood of animals treated with the optimized formulation by day 3 as opposed to the controls (MN and Tween® 20) which still had fungi on day 5. No significant increase (
) in haematological parameters was observed in mice treated with
. Conclusion. Formulation
successfully cleared Candida albicans from the blood within a shorter period than miconazole powder. This research has shown the potential of orally administered MN-loaded SRMS-based microparticles in combating systemic candidaemia.
Collapse
|
2
|
Markova E, Taneska L, Kostovska M, Shalabalija D, Mihailova L, Glavas Dodov M, Makreski P, Geskovski N, Petrushevska M, N Taravari A, Simonoska Crcarevska M. Design and evaluation of nanostructured lipid carriers loaded with Salvia officinalis extract for Alzheimer's disease treatment. J Biomed Mater Res B Appl Biomater 2022; 110:1368-1390. [PMID: 35019231 DOI: 10.1002/jbm.b.35006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Revised: 11/24/2021] [Accepted: 12/28/2021] [Indexed: 12/16/2022]
Abstract
Considering the potential of Salvia officinalis in prevention and treatment of Alzheimer's disease (AD), as well as the ability of nanostructured lipid carriers (NLC) to successfully deliver drug molecules across blood-brain barrier (BBB), the objective of this study was design, development, optimization and characterization of freeze-dried salvia officinalis extract (FSE) loaded NLC intended for intranasal administration. NLC were prepared by solvent evaporation method and the optimization was carried out using central composite design (CCD) of experiments. Further, the optimized formulation (NLCo) was coated either with chitosan (NLCc) or poloxamer (NLCp). Surface characterization of the particles demonstrated a spherical shape with smooth exterior. Particle size of optimal formulations after 0.45 μm pore size filtration ranged from 127 ± 0.68 nm to 140 ± 0.74 nm. The zeta potential was -25.6 ± 0.404 mV; 22.4 ± 1.106 mV and - 6.74 ± 0.609 mV for NLCo, NLCc, and NLCp, respectively. Differential scanning calorimetry (DSC) confirmed the formation of NLC whereas Fourier-transform infrared spectroscopy confirmed the FSE encapsulation into particles. All formulations showcased relatively high drug loading (>86.74 mcg FSE/mg solid lipid) and were characterized by prolonged and controlled release that followed Peppas-Sahlin in vitro release kinetic model. Protein adsorption studies revealed the lowest adsorption of the proteins onto NLCp (43.53 ± 0.07%) and highest protein adsorption onto NLCc (55.97 ± 0.75%) surface. The modified ORAC assay demonstrated higher antioxidative activity for NLCo (95.31 ± 1.86%) and NLCc (97.76 ± 4.00%) as compared to FSE (90.30 ± 1.53%). Results obtained from cell cultures tests pointed to the potential of prepared NLCs for FSE brain targeting and controlled release.
Collapse
Affiliation(s)
- Elena Markova
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Lea Taneska
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Monika Kostovska
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Dushko Shalabalija
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Ljubica Mihailova
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Marija Glavas Dodov
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Petre Makreski
- Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Nikola Geskovski
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Marija Petrushevska
- Institute of Pharmacology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Arben N Taravari
- University Clinic for Neurology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| | - Maja Simonoska Crcarevska
- Institute of Pharmaceutical Technology, Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia
| |
Collapse
|